PCSANM's Position on US Preventative Services Task Force Revised Guideline on Prostate Cancer Screening
However, while PCSANM is pleased with the “C” recommendation embodied in the guidelines, there are weaknesses and omissions. Why a “C” but only for men 55-69? Just because the retrospective studies to date have looked more at that age group than others ignores the fact that because prostate cancer is often slow-growing, one doesn’t see the benefits of screening sometimes for more than 10-15 years. Screening early means fewer chances of developing metastatic disease during those years, so why wait until 55 to start testing? We believe that a man’s first, baseline PSA should be around the age of 45, establishing risk and personalizing future follow up. That risk stratification is critical. PSA is just a data point; it is what you do with that information that is important.
Why does the USPSTF (that worries about over treatment if a man is diagnosed) not recommend genomic testing, MRI, liquid biopsies, and other indolent disease that might lead to active surveillance rather than treatment? Why stop testing at age 70 and classify that as a “D” recommendation? Both the American Cancer Society and National Comprehensive Cancer Network talk about testing for men with at least a ten-year life expectancy– that should be the criterion, not an arbitrary age marker. And veterans, especially those who were exposed to Agent Orange, should be included in the “higher risk” population for earlier testing, along with African-American men and men with a positive family history.
US Preventative Services Task Force (USPSTF) Revised Guideline on Prostate Cancer Screening
US Preventive Services Task Force "C" Grade for Prostate Cancer Testing
Offer or provide this service for selected patients depending on individual circumstances.
The Phase II clinical trial for talazoparib has demonstrated slowed tumor growth in some patients with advanced prostate cancer.
Approximately 1 in 6 deaths among men with metastatic prostate cancer are due to noncancer causes, according to a recent study.
Likely to boost survival in older men with non-metastatic castration-resistant prostate cancer
Many men with prostate cancer may be making treatment choices without understanding all options.
Many physicians are abandoning the transrectal biopsy due to its risks of deadly infection.
In a study, mpMRI-undetected prostate cancers had significantly lower overall Gleason score, lower maximum Gleason grade, and shorter maximum cancer core length than mpMRI detected prostate cancers.
Do Men Stick It Out?
Researches have found that those who are obese are less likely to die over the next few years.
Number of biopsies drop while preserving life expectancy
Having the right technology in place can boost patient confidence in therapy.